Complications and early mortality in percutaneous endoscopic gastrostomy placement in lombardy: A multicenter prospective cohort study.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
10 2019
Historique:
received: 09 10 2018
revised: 22 03 2019
accepted: 25 03 2019
pubmed: 24 4 2019
medline: 1 5 2020
entrez: 24 4 2019
Statut: ppublish

Résumé

Percutaneous endoscopic gastrostomy (PEG) is the most common endoscopic procedure used to provide nutritional support. To prospectively evaluate the mortality and complication incidences after PEG insertion or replacement. All patients who underwent PEG insertion or replacement were included. Details on patient characteristics, ongoing therapies, comorbidities, and indication for PEG placement/replacement were collected, along with informed consent form signatures. Early and late (30-day) complications and mortality were assessed. 950 patients (47.1% male) were enrolled in 25 centers in Lombardy, a region of Northern Italy. Patient mean age was 73 years. 69.5% of patients had ASA status 3 or 4. First PEG placement was performed in 594 patients. Complication and mortality incidences were 4.8% and 5.2%, respectively. The most frequent complication was infection (50%), followed by bleeding (32.1%), tube dislodgment (14.3%), and buried bumper syndrome (3.6%). At multivariable analysis, age (OR 1.08 per 1-year increase, 95% CI, 1.0-1.16, p = 0.010) and BMI (OR 0.86 per 1-point increase, 95% CI, 0.77-0.96, p = 0.014) were factors associated with mortality. PEG replacement was carried out in 356 patients. Thirty-day mortality was 1.8%, while complications occurred in 1.7% of patients. Our data confirm that PEG placement is a safe procedure. Mortality was not related to the procedure itself, confirming that careful patient selection is warranted.

Sections du résumé

BACKGROUND
Percutaneous endoscopic gastrostomy (PEG) is the most common endoscopic procedure used to provide nutritional support.
AIM
To prospectively evaluate the mortality and complication incidences after PEG insertion or replacement.
METHODS
All patients who underwent PEG insertion or replacement were included. Details on patient characteristics, ongoing therapies, comorbidities, and indication for PEG placement/replacement were collected, along with informed consent form signatures. Early and late (30-day) complications and mortality were assessed.
RESULTS
950 patients (47.1% male) were enrolled in 25 centers in Lombardy, a region of Northern Italy. Patient mean age was 73 years. 69.5% of patients had ASA status 3 or 4. First PEG placement was performed in 594 patients. Complication and mortality incidences were 4.8% and 5.2%, respectively. The most frequent complication was infection (50%), followed by bleeding (32.1%), tube dislodgment (14.3%), and buried bumper syndrome (3.6%). At multivariable analysis, age (OR 1.08 per 1-year increase, 95% CI, 1.0-1.16, p = 0.010) and BMI (OR 0.86 per 1-point increase, 95% CI, 0.77-0.96, p = 0.014) were factors associated with mortality. PEG replacement was carried out in 356 patients. Thirty-day mortality was 1.8%, while complications occurred in 1.7% of patients.
CONCLUSIONS
Our data confirm that PEG placement is a safe procedure. Mortality was not related to the procedure itself, confirming that careful patient selection is warranted.

Identifiants

pubmed: 31010743
pii: S1590-8658(19)30530-4
doi: 10.1016/j.dld.2019.03.024
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1380-1387

Informations de copyright

Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Auteurs

Andrea Anderloni (A)

Humanitas Research Hospital, Rozzano, Italy. Electronic address: andrea.anderloni@humanitas.it.

Milena Di Leo (M)

Humanitas Research Hospital, Rozzano, Italy; Humanitas University, Rozzano, Italy.

Franco Barzaghi (F)

Presidio Ospedaliero di Busto Arsizio, Busto Arsizio, Italy.

Rossella Semeraro (R)

Humanitas Research Hospital, Rozzano, Italy.

Gianmichele Meucci (G)

Ospedale San Giuseppe, Milan, Italy.

Roberta Marino (R)

ASST Lodi, Lodi, Italy.

Loretta Amato (L)

Humanitas Research Hospital, Rozzano, Italy.

Mauro Frigerio (M)

Azienda Sanitaria Locale della Provincia di Como, Como, Italy.

Valeria Saladino (V)

ASST OVEST Milanese, Milan, Italy.

Anna Toldi (A)

Ospedale Valduce, Como, Italy.

Guido Manfredi (G)

Ospedale Maggiore ASST Crema, Crema, Italy.

Alessandro Redaelli (A)

ASST-Monza San Gerardo, Monza, Italy.

Marcella Feliziani (M)

Azienda Ospedaliera Sant'Antonio Abate, Gallarate, Italy.

Giuseppe De Roberto (G)

Istituto Europeo di Oncologia, Milan, Italy.

Francesca Boni (F)

ASST Melegnano e Martesana, Ospedale di Vizzolo Predabissi, Milan, Italy.

Gianlorenzo Scacchi (G)

Ospedale Policlinico, Milan, Italy.

Davide Mosca (D)

Azienda Ospedaliera S. Anna, Como, Italy.

Massimo Devani (M)

ASST Rhodense, Ospedali di Rho e Garbagnate M.se, Milan, Italy.

Monica Arena (M)

Ospedale San Paolo, Milan, Italy.

Marco Massidda (M)

Istituto Clinico Humanitas Gavazzeni, Bergamo, Italy.

Paolo Zanoni (P)

Casa di cura San Francesco, Bergamo, Italy.

Camilla Ciscato (C)

ICCS Istituto Clinico Citta' Studi, Milan, Italy.

Valentina Casini (V)

ASST Bergamo EST-Ospedale Bolognini, Bergamo, Italy.

Paolo Beretta (P)

ICCS Istituto Clinico Citta' Studi, Milan, Italy.

Edoardo Forti (E)

Ospedale Niguarda Ca' Grande, Milan, Italy.

Raffaele Salerno (R)

ASST Fatebenefratelli Sacco, Milan, Italy.

Vitantonio Caramia (V)

Fondazione Salvatore Maugeri, Pavia, Italy.

Mario Bianchetti (M)

Humanitas Mater Domini, Castellanza, Italy.

Carolina Tomba (C)

ASST Santi Paolo e Carlo, Milan, Italy.

Andrea Evangelista (A)

Unit of Clinical Epidemiology, CPO, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Alessandro Repici (A)

Humanitas Research Hospital, Rozzano, Italy; Humanitas University, Rozzano, Italy.

Marco Soncini (M)

ASST Santi Paolo e Carlo, Milan, Italy.

Giovanni Maconi (G)

Gastroenterology Unit, FBF - Sacco University Hospital, Milan, Italy.

Gianpiero Manes (G)

ASST Rhodense, Ospedali di Rho e Garbagnate M.se, Milan, Italy.

Renzo Gullotta (R)

Clinica San Carlo, Paderno Dugnano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH